The outlook revision reflects Moody’s Investors Service’s expectation that WFB will maintain its current margins and increase cash flow over the next year.
Moody’s also assigned an “A2” rating to WFB’s $151.7 million of series 2016 bonds.
The rating assignment is based on a number of factors, including WFB’s strengths as a large academic medical center with a solid clinical reputation, strong market share, and solid balance sheet.
More articles on healthcare finance:
Moody’s downgrades Fremont-Rideout Health Group’s rating to ‘Ba3’
19 recent hospital outlook and credit rating actions
ZirMed takes prize for RCM platform
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
